ATG7 and neoplasm: While treatment with anti–PD-1 + HCQ significantly suppressed tumor growth rates compared with monotherapy in B16 Atg7 WT cells, no such augmentation of anti–PD-1 efficacy was observed in B16 Atg7-KO tumors treated with anti–PD-1 (Figure 2K).